MRSN Mersana Therapeutics Inc

Mersana Chief Scientific Officer, Timothy B. Lowinger, Ph.D. to chair 2018 Conference

Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) based on its Dolaflexin® and other proprietary platforms, today announced that members of the senior management and scientific teams will present at the upcoming World ADC 2018 conference in San Diego, CA, November 12-14, 2018.

“As an emerging leader in ADCs, Mersana is honored to play such a prominent role at this year’s ADC World Conference.,” said Timothy B. Lowinger, Ph.D., Chief Scientific Officer, Mersana Therapeutics, and Chairman, World ADC 2018. “The information presented and shared at this important conference by my Mersana colleagues and other industry leaders helps reinforce the rapid pace of innovation in the ADC field and the important role ADCs play in addressing significant unmet medical needs.”

Mersana will participate in the following World ADC presentations:

Title: Analytical Characterization of Dolaflexin ADCs Date/Time: Monday, November 12, 2018, 11:45 – 12:15 p.m.Presenter: David Lee, Ph.D., Senior Director, Analytical Chemistry, Mersana Therapeutics Title:  Utilizing Panels of Patient-derived Xenografts to Aid the Development of ADCs Date/Time: Tuesday, November 13, 2018, 1:30 – 2:00 p.m.Presenter: Scott D. Collins, Manager, Pharmacology, Mersana Therapeutics Title: Formulation Development Challenges for a Novel Dolaflexin ADC platformDate/Time: Tuesday, November 13, 2018, 1:30 – 2:00 p.m.Presenter: Sandra O’Connor, Executive Director, Sterile Drug Products, Mersana TherapeuticsTitle: High DAR ADCs with a Controlled Bystander Effect: From Concept to Clinical ExperienceDate/Time: Wednesday, November 14, 2018, 9:00 – 9:30 a.m.Presenter: Timothy B. Lowinger, Ph.D., Chief Scientific Officer, Mersana Therapeutics

About Mersana Therapeutics

Mersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop highly targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefit to patients.  Mersana’s product candidate XMT-1522 is in Phase 1 clinical trials in patients with advanced tumors expressing HER2, including breast cancer, non-small-cell-lung-cancer (NSCLC) and gastric cancer patients. The Company’s second product candidate, XMT-1536, is in Phase 1 clinical trials in patients with tumors expressing NaPi2b, including ovarian cancer, NSCLC and other cancers. In addition, multiple partners are using Mersana’s platform to advance their ADC pipelines.

Media Contact Paul Kidwell paulkidwell@mersana.com 617-680-1088

Investor Contact Stern Investor Relations, Inc. Christina Tartaglia christina@sternir.com 212-362-1200